MedElevator
Войти в исследования Pediatric blood & cancer · 2025
Results of a Phase II Trial for Intermediate-Risk Rhabdomyosarcoma Treatment Protocol JRS-I: A Report From the Japan Rhabdomyosarcoma Study Group.
СтатьяКлиническое исследование II фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kikuta Atsushi, Masaki Hidekazu, Hojo Hiroshi, Hata Jun-Ichi, Ohkita Hajime, Hosoi Hajime, Nakazawa Atsuko, Hinotsu Shiro, Ikeda Hitoshi, Kishimoto Seiji, Kaneko Michio, Kawai Akira, Hara Junichi, Takimoto Tetsuya, Kato Miho, Kaneko Takashi, Kosaka Yoshiyuki, Morikawa Yasuhide, Japan Rhabdomyosarcoma Study Group (JRSG)
Аннотация
PURPOSE: To evaluate the safety and efficacy of multimodality treatment with vincristine, actinomycin D, and cyclophosphamide (VAC) therapy, surgery, and radiotherapy according to the US Intergroup Rhabdomyosarcoma Study IV (IRS-IV), and to establish a central review system and standard treatment for intermediate-risk pediatric rhabdomyosarcoma in Japan.
PATIENTS AND METHODS: The Japan Rhabdomyosarcoma Study-I (JRS-I) was a single-arm, phase II trial for intermediate-risk rhabdomyosarcoma treatment with open enrollment from June 2004 to March 2009. Patients received 12 cycles of VAC every 3 weeks for 42 weeks, with local therapy beginning after Week 12. The endpoints were progression-free survival (PFS), overall survival (OS), and incidence of hepatic veno-occlusive disease (VOD).
RESULTS: Thirty-one eligible patients were enrolled, and at a median follow-up of 5.2 years, the 3-year PFS and OS for patients were 74.2% ± 7.9% (95% confidence interval [CI] 55.0%-86.2%) and 90.3% ± 5.3% (95% CI 72.9%-96.8%), respectively. VOD occurred in 3 (8%) of the 40 evaluable patients, but all recovered, and there were no deaths.
CONCLUSION: The VAC regimen for intermediate-risk rhabdomyosarcoma with the first central review system in Japan is safe and feasible, and these findings can be positioned as basic data for improving treatment outcomes in Japan.
PATIENTS AND METHODS: The Japan Rhabdomyosarcoma Study-I (JRS-I) was a single-arm, phase II trial for intermediate-risk rhabdomyosarcoma treatment with open enrollment from June 2004 to March 2009. Patients received 12 cycles of VAC every 3 weeks for 42 weeks, with local therapy beginning after Week 12. The endpoints were progression-free survival (PFS), overall survival (OS), and incidence of hepatic veno-occlusive disease (VOD).
RESULTS: Thirty-one eligible patients were enrolled, and at a median follow-up of 5.2 years, the 3-year PFS and OS for patients were 74.2% ± 7.9% (95% confidence interval [CI] 55.0%-86.2%) and 90.3% ± 5.3% (95% CI 72.9%-96.8%), respectively. VOD occurred in 3 (8%) of the 40 evaluable patients, but all recovered, and there were no deaths.
CONCLUSION: The VAC regimen for intermediate-risk rhabdomyosarcoma with the first central review system in Japan is safe and feasible, and these findings can be positioned as basic data for improving treatment outcomes in Japan.